BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report) had its price target lifted by investment analysts at HC Wainwright from $15.00 to $32.00 in a research note issued to investors on ...

Buy BCTX near 0.29 target 9.21 stop loss @ 0.29 Details The technical summary data tells us to buy BCTX near 0.29 with an upside target of 9.21. This data also tells us to set a stop loss @ 0.29 to ...

BriaCell (NASDAQ: BCTX, BCTXW) (TSX: BCT) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, has ...

Therapeutics announced that it intends to offer to sell common shares in a best-efforts public offering. ThinkEquity is acting ...

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Therapeutics trading halted, volatility trading pauseMaximize Your Portfolio with Data Driven Insights:Leverage the ...

Detailed price information for Briacell Therapeutics Corp (BCTX-Q) from The Globe and Mail including charting and trades.

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” ...

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 27, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage ...